BACKGROUND: Continued smoking after a cancer diagnosis may adversely affect treatment effectiveness, subsequent cancer risk, and survival. The prevalence of continued smoking after cancer diagnosis is understudied. METHODS: In the multi-regional Cancer Care Outcomes Research and Surveillance cohort (lung cancer [N = 2456], colorectal cancer [N = 3063]), the authors examined smoking rates at diagnosis and 5 months after diagnosis and also study factors associated with continued smoking. RESULTS: Overall, 90.2% of patients with lung cancer and 54.8% of patients with colorectal cancer reported ever smoking. At diagnosis, 38.7% of patients with lung cancer and 13.7% of patients with colorectal cancer were smoking; whereas, 5 months after diagnosis, 14.2% of patients with lung cancer and 9.0% of patients with colorectal cancer were smoking. Factors that were associated independently with continued smoking among patients with nonmetastatic lung cancer were coverage by Medicare, other public/unspecified insurance, not receiving chemotherapy, not undergoing surgery, prior cardiovascular disease, lower body mass index, lower emotional support, and higher daily ever-smoking rates (all P < .05). Factors that were associated independently with continued smoking among patients with nonmetastatic colorectal cancer were male sex, high school education, being uninsured, not undergoing surgery, and higher daily ever-smoking rates (all P < .05). CONCLUSIONS: After diagnosis, a substantial minority of patients with lung and colorectal cancers continued smoking. Patients with lung cancer had higher rates of smoking at diagnosis and after diagnosis; whereas patients with colorectal cancer were less likely to quit smoking after diagnosis. Factors that were associated with continued smoking differed between lung and colorectal cancer patients. Future smoking-cessation efforts should examine differences by cancer type, particularly when comparing cancers for which smoking is a well established risk factor versus cancers for which it is not.
BACKGROUND: Continued smoking after a cancer diagnosis may adversely affect treatment effectiveness, subsequent cancer risk, and survival. The prevalence of continued smoking after cancer diagnosis is understudied. METHODS: In the multi-regional Cancer Care Outcomes Research and Surveillance cohort (lung cancer [N = 2456], colorectal cancer [N = 3063]), the authors examined smoking rates at diagnosis and 5 months after diagnosis and also study factors associated with continued smoking. RESULTS: Overall, 90.2% of patients with lung cancer and 54.8% of patients with colorectal cancer reported ever smoking. At diagnosis, 38.7% of patients with lung cancer and 13.7% of patients with colorectal cancer were smoking; whereas, 5 months after diagnosis, 14.2% of patients with lung cancer and 9.0% of patients with colorectal cancer were smoking. Factors that were associated independently with continued smoking among patients with nonmetastatic lung cancer were coverage by Medicare, other public/unspecified insurance, not receiving chemotherapy, not undergoing surgery, prior cardiovascular disease, lower body mass index, lower emotional support, and higher daily ever-smoking rates (all P < .05). Factors that were associated independently with continued smoking among patients with nonmetastatic colorectal cancer were male sex, high school education, being uninsured, not undergoing surgery, and higher daily ever-smoking rates (all P < .05). CONCLUSIONS: After diagnosis, a substantial minority of patients with lung and colorectal cancers continued smoking. Patients with lung cancer had higher rates of smoking at diagnosis and after diagnosis; whereas patients with colorectal cancer were less likely to quit smoking after diagnosis. Factors that were associated with continued smoking differed between lung and colorectal cancerpatients. Future smoking-cessation efforts should examine differences by cancer type, particularly when comparing cancers for which smoking is a well established risk factor versus cancers for which it is not.
Authors: James L Klosky; Vida L Tyc; Ashley Hum; Shelly Lensing; Joanna Buscemi; Danette M Garces-Webb; Melissa M Hudson Journal: J Clin Oncol Date: 2009-12-14 Impact factor: 44.544
Authors: Yolanda I Garces; Darrell R Schroeder; Liza M Nirelli; Gary A Croghan; Ivana T Croghan; Robert L Foote; Richard D Hurt Journal: Am J Clin Oncol Date: 2007-10 Impact factor: 2.339
Authors: Vani Nath Simmons; Erika B Litvin; Riddhi D Patel; Paul B Jacobsen; Judith C McCaffrey; Gerold Bepler; Gwendolyn P Quinn; Thomas H Brandon Journal: Patient Educ Couns Date: 2009-10-20
Authors: Mary E Cooley; Linda Sarna; Jenny Kotlerman; Jeanne M Lukanich; Michael Jaklitsch; Sarah B Green; Raphael Bueno Journal: Lung Cancer Date: 2009-03-24 Impact factor: 5.705
Authors: Esther K Wei; Graham A Colditz; Edward L Giovannucci; Charles S Fuchs; Bernard A Rosner Journal: Am J Epidemiol Date: 2009-09-01 Impact factor: 4.897
Authors: Sandra J Japuntich; Christina M Luberto; Joanna M Streck; Nancy A Rigotti; Jennifer Temel; Michael Lanuti; Carolyn Dresler; Jennifer P Zallen; Diane Davies; Elyse R Park Journal: J Health Psychol Date: 2015-06-04
Authors: Erika Litvin Bloom; Jason A Oliver; Steven K Sutton; Thomas H Brandon; Paul B Jacobsen; Vani Nath Simmons Journal: Psychooncology Date: 2014-09-25 Impact factor: 3.894
Authors: Jessica L Burris; Jamie L Studts; Antonio P DeRosa; Jamie S Ostroff Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-08-17 Impact factor: 4.254
Authors: Graham W Warren; James R Marshall; K Michael Cummings; Benjamin Toll; Ellen R Gritz; Alan Hutson; Seyedeh Dibaj; Roy Herbst; Carolyn Dresler Journal: J Thorac Oncol Date: 2013-05 Impact factor: 15.609
Authors: Elyse R Park; Jamie S Ostroff; Giselle K Perez; Kelly A Hyland; Nancy A Rigotti; Sarah Borderud; Susan Regan; Alona Muzikansky; Emily R Friedman; Douglas E Levy; Susan Holland; Justin Eusebio; Lisa Peterson; Julia Rabin; Jacob Miller-Sobel; Irina Gonzalez; Laura Malloy; Maureen O'Brien; Suhana de León-Sanchez; C Will Whitlock Journal: Contemp Clin Trials Date: 2016-07-19 Impact factor: 2.226
Authors: Diana B Díaz; Thomas H Brandon; Steven K Sutton; Lauren R Meltzer; Hannah J Hoehn; Cathy D Meade; Paul B Jacobsen; Judith C McCaffrey; Eric B Haura; Hui-Yi Lin; Vani N Simmons Journal: Contemp Clin Trials Date: 2016-07-25 Impact factor: 2.226